The Regulatory Landscape: FCC Part 15 and IEC 60601-1-2

Wireless medical devices sold in the United States must satisfy two distinct but complementary regulatory frameworks: FCC Part 15, which governs radio frequency emissions and intentional transmitter authorisation, and IEC 60601-1-2, the collateral electromagnetic compatibility standard within the broader IEC 60601-1 family of medical electrical equipment requirements. Together, these frameworks define the emissions limits a device must not exceed and the immunity levels it must withstand without compromising patient safety or clinical performance.

The relationship between these two standards is not merely additive — it is architectural. FCC Part 15 authorisation establishes that a device’s radio transmitter meets US spectrum management requirements, while IEC 60601-1-2 establishes that the complete medical device system — including that transmitter — will not endanger patients or operators through electromagnetic interference in real-world clinical and home care environments. Engineers must plan for both frameworks from the earliest design phase, because design decisions that satisfy one framework can create compliance risks in the other.

According to the FCC, Part 15 applies to any electronic device that emits radio frequency energy, whether intentionally or unintentionally. For wireless medical devices, this typically means the device must be authorised under both Subpart B (for the device chassis and its unintentional emissions) and Subpart C (for each intentional RF transmitter, such as a Bluetooth Low Energy module or a 2.4 GHz telemetry radio). The FDA recognises IEC 60601-1-2 as a consensus standard, meaning manufacturers who declare conformance to it can use that declaration to support a 510(k) premarket notification without additional FDA review of the EMC methodology.

The IEC published the 4th edition of IEC 60601-1-2 in 2014, with widespread regulatory enforcement — including by the EU’s notified bodies — taking hold after 2019. The 4th edition marked a significant philosophical shift: rather than prescribing fixed test levels applicable to all devices, it requires manufacturers to use a risk-management process (aligned with ISO 14971) to select test levels appropriate to the device’s intended electromagnetic environment. This shift places greater engineering responsibility on the manufacturer but also creates flexibility for novel wireless technologies.

FCC Part 15 Testing: Subpart B vs. Subpart C Requirements

FCC Part 15 Subpart B governs unintentional radiators — devices that generate RF energy as a by-product of digital operation — while Subpart C governs intentional radiators, meaning devices that deliberately transmit RF energy for communication purposes. Most wireless medical devices contain both categories of emitter and therefore require testing under both subparts, each with its own test methodology, frequency range, and authorisation pathway.

Under Subpart B, radiated emissions are measured in a semi-anechoic chamber or an open-area test site (OATS) across the frequency range from 30 MHz to at least 1 GHz (or up to the 5th harmonic of the highest internal frequency for devices operating above 1 GHz). Conducted emissions are measured on the mains power port from 150 kHz to 30 MHz using a line impedance stabilisation network (LISN). Limits vary by device class: Class A devices are intended for commercial environments and carry less stringent limits, while Class B devices — which include most consumer and medical products intended for home use — must meet tighter limits that account for proximity to sensitive residential receivers.

For Subpart C intentional transmitters, the test scope depends on the frequency band and modulation scheme. Transmitters operating in unlicensed bands (such as the 2.4 GHz ISM band used by Bluetooth and Wi-Fi, or the 900 MHz band used by some medical telemetry systems) must demonstrate compliance with the conducted and radiated spurious emission limits specified in FCC Part 15.247 or Part 15.249, as applicable. Devices operating close to the human body — such as wearable cardiac monitors or continuous glucose monitors — may additionally require specific absorption rate (SAR) testing under FCC Part 1.1310 and the associated OET Bulletin 65 methodology if the transmitter operates at power levels and frequencies that could deposit significant RF energy in tissue.

A practical shortcut available to many medical device engineers is the use of a pre-certified modular transmitter — an RF module that already holds its own FCC ID under a grant of authorisation issued to the module manufacturer. When a pre-certified module is integrated into a host medical device, the host manufacturer can often avoid full Subpart C re-testing of the transmitter, provided the integration conditions specified in the module’s grant are satisfied. These conditions typically include maintaining specified antenna separation distances, not exceeding the module’s rated transmit power, and ensuring the host device chassis does not degrade the module’s emissions performance. However, system-level immunity testing under IEC 60601-1-2 remains fully required regardless of the module’s FCC certification status.

IEC 60601-1-2 Edition 4: Risk-Managed EMC for Medical Devices

IEC 60601-1-2 Edition 4 requires manufacturers to define the intended electromagnetic environment of their device before selecting any test levels — a fundamental departure from earlier editions that applied uniform test levels to all devices regardless of deployment context. This risk-management approach, aligned with ISO 14971, means that a cardiac pacemaker programmer used exclusively in a shielded electrophysiology lab and a home-use blood glucose monitor will face different immunity test levels, because their electromagnetic environments carry different interference profiles.

The standard requires manufacturers to document an essential performance definition — a precise statement of the clinical functions whose loss or degradation could directly harm the patient or operator — and then demonstrate that those functions are preserved under all applicable disturbance tests. For a wireless pulse oximeter, essential performance might include the accuracy of SpO₂ readings within ±2% and the integrity of alarm outputs; for an implantable cardiac monitor, it might include the accurate detection of arrhythmia episodes. Defining essential performance is a clinical and engineering exercise that must precede test planning, because it determines which test failures constitute a safety issue and which represent acceptable degradation.

“Defining essential performance is the most consequential engineering decision in IEC 60601-1-2 compliance — it determines which test failures are safety failures and which are merely inconveniences.”

The Edition 4 test programme covers both emissions and immunity. On the emissions side, the standard references CISPR 11 (for industrial, scientific, and medical equipment) or CISPR 32 (for multimedia equipment) as the applicable emissions standard depending on device classification. On the immunity side, the programme includes electrostatic discharge (ESD) per IEC 61000-4-2, radiated RF immunity per IEC 61000-4-3 (covering 80 MHz to 2.7 GHz at field strengths from 3 V/m to 30 V/m depending on environment), electrical fast transient (EFT) per IEC 61000-4-4, surge per IEC 61000-4-5, conducted RF immunity per IEC 61000-4-6, power frequency magnetic field per IEC 61000-4-8, and voltage dips and interruptions per IEC 61000-4-11. Wireless devices must additionally address immunity at the frequencies used by their own transmitters — a unique requirement that reflects the possibility of self-interference between the device’s transmitter and its own sensitive analogue circuitry.

Engineering the Test Sequence: From Pre-Compliance to Accredited Lab

A structured test sequence — moving from early-stage pre-compliance screening through to accredited laboratory testing — reduces the cost and schedule risk of EMC validation by catching design failures before they become expensive late-stage surprises. Pre-compliance testing, conducted in-house or at a commercial EMC facility without formal accreditation, allows engineers to iterate on PCB layout, shielding, filtering, and firmware before committing to a full accredited test campaign.

Phase 1: Pre-Compliance Screening

Pre-compliance emissions screening uses a near-field probe set and a spectrum analyser to identify dominant emission sources on the PCB — clock harmonics, switching regulator noise, and high-speed data bus emissions are common culprits in medical devices. Engineers map emission hotspots against the applicable FCC Part 15 Class B limits (translated to near-field equivalents using conservative correlation factors) and implement mitigation measures: copper pours, ferrite beads, decoupling capacitor placement, and PCB trace routing changes. This phase should also include a preliminary radiated immunity walk-test using a calibrated RF signal generator and a small loop or horn antenna to identify any sensitivity in the device’s analogue front-end or wireless receiver at the frequencies of concern.

Phase 2: Accredited Emissions Testing

Accredited emissions testing for FCC Part 15 Subpart B is conducted in a semi-anechoic chamber or OATS by an FCC-recognised laboratory accredited under the NVLAP or A2LA programmes. The device is configured in its worst-case emissions state — maximum processor load, active wireless transmitter, and all peripheral interfaces active — and measured at multiple antenna heights and device orientations to find the peak emission. Test reports must include the measurement uncertainty budget, antenna calibration records, and a comparison of measured levels against the applicable limits with margin. For Subpart C, the intentional transmitter is tested for conducted spurious emissions on the antenna port and for radiated spurious emissions in the far field.

Phase 3: IEC 60601-1-2 Immunity Testing

IEC 60601-1-2 immunity testing is conducted at a laboratory accredited to ISO/IEC 17025 for the relevant test methods. The test plan, derived from the risk management file, specifies which immunity tests apply, the test levels selected for each environment, the device operating mode during each test, the essential performance criteria to be monitored, and the pass/fail criteria. During radiated RF immunity testing per IEC 61000-4-3, the device is placed in a shielded room with a biconical or log-periodic antenna and exposed to a swept continuous wave field at the specified level; a technician monitors the device’s outputs and displays for any deviation from essential performance. ESD testing per IEC 61000-4-2 is applied to all accessible surfaces and connectors at contact and air discharge levels appropriate to the environment.

Regulatory Submissions: Packaging EMC Evidence for FDA and CE Mark

EMC compliance evidence must be packaged differently for FDA 510(k) submissions and CE Mark technical files, because the two frameworks have different documentation conventions — even when the underlying test data is identical. Engineers who understand both packaging requirements from the outset can structure their test programme to generate a single set of test reports that satisfies both submissions without redundant testing.

FDA 510(k) EMC Documentation

For FDA 510(k) submissions, the EMC section should include a declaration of conformance to IEC 60601-1-2 as an FDA-recognised consensus standard (listed in the FDA’s database of recognised standards), the complete IEC 60601-1-2 test report from an accredited laboratory, the risk management file excerpt showing how the intended electromagnetic environment was determined and how essential performance was defined, and the FCC authorisation documentation (either the FCC ID grant of authorisation for certified devices, or the Declaration of Conformity for DoC devices). The FDA does not require that the test laboratory be FDA-accredited — accreditation to ISO/IEC 17025 for the relevant test methods is sufficient. According to guidance published by the FDA, manufacturers who declare conformance to a recognised consensus standard must submit a conformance declaration referencing the specific edition of the standard tested against, because the FDA’s recognition database is edition-specific.

CE Mark Technical File Under EU MDR

For CE Mark under EU MDR 2017/745, the technical file must include the IEC 60601-1-2 conformance declaration as part of the General Safety and Performance Requirements (GSPR) checklist, the complete test reports, and a justification for the selected electromagnetic environment. The notified body will review whether the risk management process adequately considered electromagnetic interference as a hazard under ISO 14971, and whether the essential performance definition is clinically defensible. For devices classified as Class IIa or above under MDR, the notified body will scrutinise the EMC documentation as part of its conformity assessment. As noted in standards guidance from ISO, the risk management file must demonstrate a clear traceability chain from hazard identification through risk control measures to residual risk acceptance — and EMC-related hazards must be explicitly addressed within that chain.

A common documentation gap in both submission types is the absence of a clearly defined electromagnetic environment in the instructions for use (IFU). IEC 60601-1-2 Edition 4 requires manufacturers to include in the IFU a description of the electromagnetic environment in which the device is intended to be used, a list of essential performance criteria, and — for devices that include intentional transmitters — a statement of the frequency bands used and the transmit power. This IFU content is reviewed by both FDA reviewers and notified bodies as evidence that the manufacturer has adequately informed users of the device’s electromagnetic limitations. The PatSnap medical device intelligence platform can help engineering teams benchmark their IFU documentation approaches against those of competitors by analysing publicly available regulatory filings and patent specifications. Teams can also use PatSnap’s R&D intelligence tools to identify emerging EMC mitigation technologies before they appear in competitor products.